Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.

Choudhry A, O'Brien SM.

Drugs Today (Barc). 2017 Dec;53(12):653-665. doi: 10.1358/dot.2017.53.12.2737934.

PMID:
29517084
2.

Inotuzumab Ozogamicin: First Global Approval.

Lamb YN.

Drugs. 2017 Sep;77(14):1603-1610. doi: 10.1007/s40265-017-0802-5. Review.

PMID:
28819740
3.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS.

N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.

4.

Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.

Dahl J, Marx K, Jabbour E.

Expert Rev Hematol. 2016;9(4):329-34. doi: 10.1586/17474086.2016.1143771. Epub 2016 Mar 22.

PMID:
26783163
5.

Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Yurkiewicz IR, Muffly L, Liedtke M.

Drug Des Devel Ther. 2018 Jul 24;12:2293-2300. doi: 10.2147/DDDT.S150317. eCollection 2018. Review.

6.

Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.

Al-Salama ZT.

Target Oncol. 2018 Aug;13(4):525-532. doi: 10.1007/s11523-018-0584-z. Review.

PMID:
30090971
7.

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI.

Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.

PMID:
28687420
8.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.

Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S.

Cancer. 2013 Aug 1;119(15):2728-36. doi: 10.1002/cncr.28136. Epub 2013 Apr 30.

9.

Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.

Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI.

Cancer. 2018 May 15;124(10):2151-2160. doi: 10.1002/cncr.31317. Epub 2018 Mar 6.

10.

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

Thota S, Advani A.

Eur J Haematol. 2017 May;98(5):425-434. doi: 10.1111/ejh.12862. Epub 2017 Mar 9. Review.

PMID:
28152223
11.

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

Shor B, Gerber HP, Sapra P.

Mol Immunol. 2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7. Review.

PMID:
25304309
12.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E.

Lancet Oncol. 2018 Feb;19(2):240-248. doi: 10.1016/S1470-2045(18)30011-1. Epub 2018 Jan 16.

PMID:
29352703
13.

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Ricart AD.

Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486. Review.

14.

Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.

Morley NJ, Marks DI.

Expert Rev Anticancer Ther. 2016;16(2):159-64. doi: 10.1586/14737140.2016.1131614. Epub 2016 Jan 28. Review.

15.

Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.

George B, Kantarjian H, Jabbour E, Jain N.

Immunotherapy. 2016 Feb;8(2):135-43. doi: 10.2217/imt.15.108. Epub 2016 Jan 18. Review.

16.

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S.

Lancet Oncol. 2012 Apr;13(4):403-11. doi: 10.1016/S1470-2045(11)70386-2. Epub 2012 Feb 21.

PMID:
22357140
17.

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

Paul S, Rausch CR, Kantarjian H, Jabbour EJ.

Future Oncol. 2017 Oct;13(25):2233-2242. doi: 10.2217/fon-2017-0233. Epub 2017 Aug 4. Review.

PMID:
28776425
18.

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR.

AAPS J. 2016 Sep;18(5):1101-1116. doi: 10.1208/s12248-016-9929-7. Epub 2016 May 19.

PMID:
27198897
19.

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH.

Leukemia. 2012 Feb;26(2):255-64. doi: 10.1038/leu.2011.206. Epub 2011 Aug 26.

PMID:
21869836
20.

Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.

Ogura M, Tobinai K, Hatake K, Davies A, Crump M, Ananthakrishnan R, Ishibashi T, Paccagnella ML, Boni J, Vandendries E, MacDonald D.

Clin Cancer Res. 2016 Oct 1;22(19):4807-4816. Epub 2016 May 6.

Supplemental Content

Support Center